by Bullous pemphigoid is an acquired autoimmune skin disorder characterized by the presence of IgG autoantibodies directed against the hemidesmosomal components of the dermal–epidermal basement membrane zone, which causes subepidermal blistering. The typical clinical presentation includes tense bullae and urticarial plaques, often in flexural areas of the body. The increasing cases of bullous pemphigoid globally have raised awareness regarding timely diagnosis and treatment. Bullous pemphigoid usually occurs in adults over the age of 60. The rising geriatric population prone to develop bullous pemphigoid is a key factor estimated to drive the growth of the Bullous Pemphigoid Market.
The Bullous Pemphigoid Marketis estimated to be valued at US$ 1.4 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the bullous pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. GlaxoSmithKline’s Rituximab (Rituxan) and Novartis’ Eculizumab (Soliris) are the leading biological disease-modifying medications for bullous pemphigoid treatment.
The rising incidences of bullous pemphigoid cases globally present lucrative growth opportunities for players in the market. Furthermore, increasing R&D investments by key players for development of novel and targeted treatment options will augment the market growth during the forecast period.
North America dominates the Bullous Pemphigoid Market owing to the high prevalence of bullous pemphigoid in the US and Canada. However, Asia Pacific is estimated to witness the highest CAGR over the forecast period with increasing healthcare expenditures and improving access to diagnosis and treatment in countries like China and India.
Market Drivers
The rising geriatric population is a major driver of the bullous pemphigoid market. People aged 60 years and older have the highest vulnerability to develop bullous pemphigoid. According to WHO, the world’s geriatric population is projected to reach nearly 2.1 billion by 2050 from 703 million in 2019. This will significantly increase the patient pool globally for bullous pemphigoid over the coming years. Furthermore, increasing awareness about disease recognition and management among physicians and patients is encouraging early diagnosis and treatment, thus propelling the market growth.
PEST Analysis
Political: Regulations related to drug manufacturing and approval processes have significant influence over the growth prospects of the bullous pemphigoid market. Changes or amendments in such regulatory frameworks directly impact R&D activities and new drug launches.
Economic: Rising healthcare expenditures of consumers and increasing demand for effective drugs for rare diseases are positive factors contributing to revenue generation opportunities for players in the bullous pemphigoid market.
Social: Growing awareness about rare skin diseases and availability of various treatment options provide impetus to patients seeking diagnosis and therapy. This improves the treatment seeking rate.
Technological: Advanced biotechnological and pharmaceutical research continues to aid drug discovery for complex autoimmune disorders like bullous pemphigoid. Technological innovations enable better drug targeting and enhanced efficacy. Development of novel drug delivery systems also influences market expansion.
The bullous pemphigoid market currently realizes a major share of its total value from developed regions including North America, Western Europe, and Japan owing to high healthcare expenditures, sophisticated infrastructure, and growing disease awareness. The U.S. alone accounts for over 35% of global market revenue due to presence of advanced medical facilities and favorable reimbursement policies.
Among emerging markets, Asia Pacific is projected to witness the fastest growth during the forecast period driven by increasing healthcare access, expanding patient pool, and improving economic conditions. The bullous pemphigoid treatment market in China, India, and other Asian countries is expected to represent significant gain in revenue contribution owing to rising disposable incomes, growing medical tourism, and gradual enhancement in healthcare infrastructure and research capabilities.
What Are The Key Data Covered In This Bullous Pemphigoid Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Bullous Pemphigoid Market’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Bullous Pemphigoid Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Bullous Pemphigoid Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Bullous Pemphigoid Market vendors
FAQ’s
Q.1 What are the main factors influencing the Bullous Pemphigoid Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Bullous Pemphigoid Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Bullous Pemphigoid Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
